Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

4.495 -0.035 (-0.77%)
Streaming Delayed Price Updated: 11:23 AM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
GOODRX HOLDINGS, INC. (NASDAQ: GDRX) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against GoodRx Holdings, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
GDRX Alert: Rosen, Skilled Investor Counsel, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GDRX
From The Rosen Law Firm, P.A.
Via Business Wire
Why GoodRx Surged Today
The prescription-drug upstart got an upgrade from Wall Street. 
Via The Motley Fool
The Latest Analyst Ratings For GoodRx Holdings
 
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
GDRX INVESTOR ALERT: Kessler Topaz Meltzer & Check, LLP Files A Securities Fraud Class Action Lawsuit Against GoodRX Holdings, Inc. And Encourages Investors With Losses To Contact The Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
GoodRx Announces Date for First Quarter 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
In-Depth Examination Of 4 Analyst Recommendations For GoodRx Holdings
 
Via Benzinga
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst. 
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says
Wells Fargo's upgrade of GoodRx Holdings. Analysts anticipate strong revenue visibility and EBITDA margins, setting the stage for potential stock outperformance in 2024-2025. 
Via Benzinga
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday. Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
GoodRx Interim CEO Extends Commitment to Company
From GoodRx Holdings, Inc.
Via Business Wire
These Analysts Increase Their Forecasts On GoodRx Following Q4 Earnings
GoodRx Holdings, Inc. (NASDAQ: GDRX) reported upbeat fourth-quarter FY23 results and issued first-quarter revenue guidance above estimates. 
Via Benzinga
Why GoodRx Stock Soared Today
The company beat Q4 estimates, announced a new share repurchase authorization, and issued strong guidance. 
Via The Motley Fool
GoodRx (GDRX) Q4 2023 Earnings Call Transcript
GDRX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Why Is Telemedicine Firm GoodRx's Shares Surging Today
GoodRx Holdings reported strong Q4 results and issued above-estimate revenue guidance for FY24. Revenue and adjusted EBITDA increased, company also announced new stock repurchase program. 
Via Benzinga
GoodRx Reports Fourth Quarter and Full Year 2023 Results
From GoodRx Holdings, Inc.
Via Business Wire
This healthcare stock making a buzz with 160% growth
Healthcare stocks are typically on the boring side of the spectrum, that is until you add a bit of technology and the right niche to them. 
Via MarketBeat
Topics Economy
GoodRx to Participate in Upcoming Investor Conferences
From GoodRx Holdings, Inc.
Via Business Wire
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
GoodRx Announces Date for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Announces Proposed Refinancing of First Lien Credit Facilities
From GoodRx Holdings, Inc.
Via Business Wire
The GoodRx Effect: Delivering a Transformative Impact on the U.S. Healthcare System through Prescription Savings
From GoodRx
Via Business Wire
Prescription Drug Discount Provider GoodRx Expects To Build Momentum In 2024, Stock Soars
GoodRx Holdings Inc (NASDAQ: GDRX) provided preliminary Q4 FY23 revenue of $195 million-$197 million, up 6%-7% Y/Y, versus the consensus of $190.77 million. 
Via Benzinga
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024
From GoodRx Holdings, Inc.
Via Business Wire
Election Edge: 7 Stocks to Snag Before the 2024 Presidential Race Heats Up
Election stocks include companies at the center of national conversation and those likely to get increased government funding. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.